BillionToOne Advances Liquid Biopsy Technology Presentations
Innovations in liquid biopsy technology are transforming the landscape of cancer diagnostics. BillionToOne, a molecular diagnostics company, is set to present groundbreaking data at the American Association of Cancer Research (AACR) Annual Meeting. The company, dedicated to providing powerful and accurate tests, will unveil details about their latest advancements.
The focus at AACR will center on enhancing precision in tumor burden measurement through innovative liquid biopsy techniques. Notably, these advancements allow for a more accurate inference of in-tissue copy number from circulating tumor DNA (ctDNA) and the detection of a unique non-tumor derived pseudogene related to GNA11.
Abstract Presentations at AACR Annual Meeting
BillionToOne will showcase several abstracts during the AACR Annual Meeting. Each submission reflects their commitment to advancing the field further:
Tumor Fraction Estimation
The first presentation discusses the use of copy number signals derived from a liquid biopsy assay. This approach is crucial for accurately estimating tumor fraction and inferring tissue copy numbers.
Novel GNA11 Pseudogene Detection
The second abstract focuses on the detection of a newly identified GNA11 processed pseudogene from cell-free DNA (cfDNA). This finding has significant implications for liquid biopsy applications and potential clinical decision-making.
Methylated Tumor DNA Measurements
The final abstract highlights research correlating circulating cell-free methylated tumor DNA measurements with plasma variant allele frequency-based tumor fraction estimates. This correlation demonstrates the robustness of ctDNA as a marker for monitoring cancer.
Dr. Gary Palmer, Chief Medical Officer for Oncology at BillionToOne, stated, "These data presented at AACR represent our dedication to advancing liquid biopsy testing with our proprietary single molecule precision technology. Our goal is to establish new standards for what can be achieved using plasma-based tests. These innovations improve ctDNA-based cancer profiling and monitoring, ultimately leading to more informed treatment decisions for patients."
About BillionToOne
BillionToOne, headquartered in Menlo Park, California, aims to revolutionize the field of molecular diagnostics by enhancing accuracy, efficiency, and accessibility. The company's unique single-molecule NGS (smNGS) platform includes patented Quantitative Counting Template (QCT) technology, which can accurately count DNA molecules at the single-molecule level.
In their quest to improve cancer diagnostics, BillionToOne continues to push the boundaries of what molecular diagnostics can achieve. Their commitment to delivering precise and accessible tests sets them apart in the industry.
Frequently Asked Questions
What innovations will BillionToOne present at AACR?
BillionToOne will showcase advancements in liquid biopsy technology, including tumor burden measurement and the detection of a novel GNA11 pseudogene.
Who is the Chief Medical Officer of BillionToOne?
Dr. Gary Palmer serves as the Chief Medical Officer for Oncology at BillionToOne.
What is the significance of ctDNA in cancer diagnostics?
Circulating tumor DNA (ctDNA) provides critical insights into tumor characteristics, aiding in monitoring and treatment decisions.
Where is BillionToOne headquartered?
BillionToOne is headquartered in Menlo Park, California.
How does the Quantitative Counting Template technology work?
This patented technology enables accurate counting of DNA molecules at the single-molecule level, enhancing the precision of molecular diagnostics.
